COPD is characterised by tissue destruction and inflammation. Given the lack of curative treatments and the progressive nature of the disease, new treatments for COPD are highly relevant. In vitro cell culture and animal studies have demonstrated that mesenchymal stromal cells (MSCs) have the capacity to modify immune responses and to enhance tissue repair. These properties of MSCs provided a rationale to investigate their potential for treatment of a variety of diseases, including COPD. Preclinical models support the hypothesis that MSCs may have clinical efficacy in COPD. However, although clinical trials have demonstrated the safety of MSC treatment, thus far they have not provided evidence for MSC efficacy in the treatment of COPD. In this review, we discuss the rationale for MSC-based cell therapy in COPD, the main findings from in vitro and in vivo preclinical COPD model studies, clinical trials in patients with COPD and directions for further research.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5969341PMC
http://dx.doi.org/10.1136/thoraxjnl-2017-210672DOI Listing

Publication Analysis

Top Keywords

mesenchymal stromal
8
stromal cells
8
copd
8
clinical trials
8
cells novel
4
novel therapy
4
treatment
4
therapy treatment
4
treatment chronic
4
chronic obstructive
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!